Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study
Introduction: China has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades. Method: Data on disease burden related to PD in...
Gespeichert in:
Veröffentlicht in: | Neuroepidemiology 2023-03, Vol.57 (1), p.51-64 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 64 |
---|---|
container_issue | 1 |
container_start_page | 51 |
container_title | Neuroepidemiology |
container_volume | 57 |
creator | Zheng, Zhilin Zhu, Zeyu Zhou, Chen Cao, Lanxiao Zhao, Guohua |
description | Introduction: China has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades. Method: Data on disease burden related to PD in China were retrieved from the Global Burden of Disease (GBD) 2019 study. The estimated annual percentage changes (EAPCs) were calculated to assess temporal trends, and the ratio of years lived with disability (YLDs) to disability-adjusted life years (DALYs) was used as an index to evaluate the healthcare system. Result: Nationally, the burden of PD increased from 1990 to 2019. Although the age-standardized incidence rate (ASIR) increased, the age-standardized death rate (ASDR) and age-standardized DALY rate both decreased. Age-standardized rates of PD in males remained higher than those in females, but trends in ASDR and the age-standardized DALY rate for females showed a pronounced decrease. The most remarkable increase in the ASIR was in individuals aged 45–49 years, with an EAPC of 1.74 (95% confidence interval, 1.26–2.21). The YLDs:DALYs ratio continuously increased compared with global figures and even with countries with high sociodemographic index (SDI). Conclusion: Although ASDR and age-standardized DALY rates for PD have been declining, the burden of PD still needs attention as the total numbers have increased over the period. Generally, the greater burden of PD was in males. A sound health system with services tailored to PD continues to be required in the future. |
doi_str_mv | 10.1159/000527372 |
format | Article |
fullrecord | <record><control><sourceid>gale_karge</sourceid><recordid>TN_cdi_gale_infotracmisc_A742661836</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A742661836</galeid><sourcerecordid>A742661836</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-824dbaf174e1e6a4e9c67cbb5a194746f5276712e919b485a678185f7727c1533</originalsourceid><addsrcrecordid>eNpt0ltrFDEUB_AgFrtWH3wXCRTEgltzmdx8kbq9KBQV1OeQmUl2YmeSNZkR-uZ38Bv6SZxl2rELJQ-BnN_5wwkHgGcYHWPM1BuEECOCCvIALHBB6BIRJB-CBSIMLxllaB88zvkHQiOW6hHYp5xIyaVcgOb9kGobYHTwi0lXPuQY4KnP1mQLfYCrxgfzGmKl0N_ffwjC6i0896H2YZ2hS7GDfWPh9h1etLE0LfwfeBvztR_q6ydgz5k226c39wH4fn72bfVhefn54uPq5HJZMUL7pSRFXRqHRWGx5aawquKiKktmsCpEwd04KBeYWIVVWUhmuJBYMicEERVmlB6Ad1PuZig7W1c29Mm0epN8Z9K1jsbr3UrwjV7HXxojxAuqtgmvbhJS_DnY3OvO58q2rQk2DlkTQRQjBFMx0sOJrk1rtQ8ujpHVlusTURDOsaR8VMf3qPHUtvNVDNb58X2n4eWdhsaatm9ybIfex5B34dEEqxRzTtbNc2Kkt6uh59UY7Yu7HzPL210YwfMJXJm0tmkGc__hveVPZ6eT0Jva0X-G68PI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2729522137</pqid></control><display><type>article</type><title>Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study</title><source>MEDLINE</source><source>Karger Journals</source><creator>Zheng, Zhilin ; Zhu, Zeyu ; Zhou, Chen ; Cao, Lanxiao ; Zhao, Guohua</creator><creatorcontrib>Zheng, Zhilin ; Zhu, Zeyu ; Zhou, Chen ; Cao, Lanxiao ; Zhao, Guohua</creatorcontrib><description>Introduction: China has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades. Method: Data on disease burden related to PD in China were retrieved from the Global Burden of Disease (GBD) 2019 study. The estimated annual percentage changes (EAPCs) were calculated to assess temporal trends, and the ratio of years lived with disability (YLDs) to disability-adjusted life years (DALYs) was used as an index to evaluate the healthcare system. Result: Nationally, the burden of PD increased from 1990 to 2019. Although the age-standardized incidence rate (ASIR) increased, the age-standardized death rate (ASDR) and age-standardized DALY rate both decreased. Age-standardized rates of PD in males remained higher than those in females, but trends in ASDR and the age-standardized DALY rate for females showed a pronounced decrease. The most remarkable increase in the ASIR was in individuals aged 45–49 years, with an EAPC of 1.74 (95% confidence interval, 1.26–2.21). The YLDs:DALYs ratio continuously increased compared with global figures and even with countries with high sociodemographic index (SDI). Conclusion: Although ASDR and age-standardized DALY rates for PD have been declining, the burden of PD still needs attention as the total numbers have increased over the period. Generally, the greater burden of PD was in males. A sound health system with services tailored to PD continues to be required in the future.</description><identifier>ISSN: 0251-5350</identifier><identifier>EISSN: 1423-0208</identifier><identifier>DOI: 10.1159/000527372</identifier><identifier>PMID: 36288688</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Analysis ; China ; China - epidemiology ; Female ; Global Burden of Disease ; Global Health ; Humans ; Incidence ; Male ; Medical research ; Medicine, Experimental ; Mortality ; Original Paper ; Parkinson Disease - epidemiology ; Parkinson's disease ; Quality-Adjusted Life Years</subject><ispartof>Neuroepidemiology, 2023-03, Vol.57 (1), p.51-64</ispartof><rights>2022 The Author(s). Published by S. Karger AG, Basel</rights><rights>2022 The Author(s). Published by S. Karger AG, Basel.</rights><rights>COPYRIGHT 2023 S. Karger AG</rights><rights>Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-824dbaf174e1e6a4e9c67cbb5a194746f5276712e919b485a678185f7727c1533</citedby><cites>FETCH-LOGICAL-c523t-824dbaf174e1e6a4e9c67cbb5a194746f5276712e919b485a678185f7727c1533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,2423,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36288688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Zhilin</creatorcontrib><creatorcontrib>Zhu, Zeyu</creatorcontrib><creatorcontrib>Zhou, Chen</creatorcontrib><creatorcontrib>Cao, Lanxiao</creatorcontrib><creatorcontrib>Zhao, Guohua</creatorcontrib><title>Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study</title><title>Neuroepidemiology</title><addtitle>Neuroepidemiology</addtitle><description>Introduction: China has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades. Method: Data on disease burden related to PD in China were retrieved from the Global Burden of Disease (GBD) 2019 study. The estimated annual percentage changes (EAPCs) were calculated to assess temporal trends, and the ratio of years lived with disability (YLDs) to disability-adjusted life years (DALYs) was used as an index to evaluate the healthcare system. Result: Nationally, the burden of PD increased from 1990 to 2019. Although the age-standardized incidence rate (ASIR) increased, the age-standardized death rate (ASDR) and age-standardized DALY rate both decreased. Age-standardized rates of PD in males remained higher than those in females, but trends in ASDR and the age-standardized DALY rate for females showed a pronounced decrease. The most remarkable increase in the ASIR was in individuals aged 45–49 years, with an EAPC of 1.74 (95% confidence interval, 1.26–2.21). The YLDs:DALYs ratio continuously increased compared with global figures and even with countries with high sociodemographic index (SDI). Conclusion: Although ASDR and age-standardized DALY rates for PD have been declining, the burden of PD still needs attention as the total numbers have increased over the period. Generally, the greater burden of PD was in males. A sound health system with services tailored to PD continues to be required in the future.</description><subject>Analysis</subject><subject>China</subject><subject>China - epidemiology</subject><subject>Female</subject><subject>Global Burden of Disease</subject><subject>Global Health</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mortality</subject><subject>Original Paper</subject><subject>Parkinson Disease - epidemiology</subject><subject>Parkinson's disease</subject><subject>Quality-Adjusted Life Years</subject><issn>0251-5350</issn><issn>1423-0208</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>EIF</sourceid><recordid>eNpt0ltrFDEUB_AgFrtWH3wXCRTEgltzmdx8kbq9KBQV1OeQmUl2YmeSNZkR-uZ38Bv6SZxl2rELJQ-BnN_5wwkHgGcYHWPM1BuEECOCCvIALHBB6BIRJB-CBSIMLxllaB88zvkHQiOW6hHYp5xIyaVcgOb9kGobYHTwi0lXPuQY4KnP1mQLfYCrxgfzGmKl0N_ffwjC6i0896H2YZ2hS7GDfWPh9h1etLE0LfwfeBvztR_q6ydgz5k226c39wH4fn72bfVhefn54uPq5HJZMUL7pSRFXRqHRWGx5aawquKiKktmsCpEwd04KBeYWIVVWUhmuJBYMicEERVmlB6Ad1PuZig7W1c29Mm0epN8Z9K1jsbr3UrwjV7HXxojxAuqtgmvbhJS_DnY3OvO58q2rQk2DlkTQRQjBFMx0sOJrk1rtQ8ujpHVlusTURDOsaR8VMf3qPHUtvNVDNb58X2n4eWdhsaatm9ybIfex5B34dEEqxRzTtbNc2Kkt6uh59UY7Yu7HzPL210YwfMJXJm0tmkGc__hveVPZ6eT0Jva0X-G68PI</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Zheng, Zhilin</creator><creator>Zhu, Zeyu</creator><creator>Zhou, Chen</creator><creator>Cao, Lanxiao</creator><creator>Zhao, Guohua</creator><general>S. Karger AG</general><scope>M--</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230301</creationdate><title>Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study</title><author>Zheng, Zhilin ; Zhu, Zeyu ; Zhou, Chen ; Cao, Lanxiao ; Zhao, Guohua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-824dbaf174e1e6a4e9c67cbb5a194746f5276712e919b485a678185f7727c1533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analysis</topic><topic>China</topic><topic>China - epidemiology</topic><topic>Female</topic><topic>Global Burden of Disease</topic><topic>Global Health</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mortality</topic><topic>Original Paper</topic><topic>Parkinson Disease - epidemiology</topic><topic>Parkinson's disease</topic><topic>Quality-Adjusted Life Years</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Zhilin</creatorcontrib><creatorcontrib>Zhu, Zeyu</creatorcontrib><creatorcontrib>Zhou, Chen</creatorcontrib><creatorcontrib>Cao, Lanxiao</creatorcontrib><creatorcontrib>Zhao, Guohua</creatorcontrib><collection>Karger Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuroepidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Zhilin</au><au>Zhu, Zeyu</au><au>Zhou, Chen</au><au>Cao, Lanxiao</au><au>Zhao, Guohua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study</atitle><jtitle>Neuroepidemiology</jtitle><addtitle>Neuroepidemiology</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>57</volume><issue>1</issue><spage>51</spage><epage>64</epage><pages>51-64</pages><issn>0251-5350</issn><eissn>1423-0208</eissn><abstract>Introduction: China has the most people with Parkinson disease (PD) in the world and is estimated to have over half of the worldwide PD population. The objective of this study was to analyze the corresponding burden of PD in China for the past decades. Method: Data on disease burden related to PD in China were retrieved from the Global Burden of Disease (GBD) 2019 study. The estimated annual percentage changes (EAPCs) were calculated to assess temporal trends, and the ratio of years lived with disability (YLDs) to disability-adjusted life years (DALYs) was used as an index to evaluate the healthcare system. Result: Nationally, the burden of PD increased from 1990 to 2019. Although the age-standardized incidence rate (ASIR) increased, the age-standardized death rate (ASDR) and age-standardized DALY rate both decreased. Age-standardized rates of PD in males remained higher than those in females, but trends in ASDR and the age-standardized DALY rate for females showed a pronounced decrease. The most remarkable increase in the ASIR was in individuals aged 45–49 years, with an EAPC of 1.74 (95% confidence interval, 1.26–2.21). The YLDs:DALYs ratio continuously increased compared with global figures and even with countries with high sociodemographic index (SDI). Conclusion: Although ASDR and age-standardized DALY rates for PD have been declining, the burden of PD still needs attention as the total numbers have increased over the period. Generally, the greater burden of PD was in males. A sound health system with services tailored to PD continues to be required in the future.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>36288688</pmid><doi>10.1159/000527372</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0251-5350 |
ispartof | Neuroepidemiology, 2023-03, Vol.57 (1), p.51-64 |
issn | 0251-5350 1423-0208 |
language | eng |
recordid | cdi_gale_infotracmisc_A742661836 |
source | MEDLINE; Karger Journals |
subjects | Analysis China China - epidemiology Female Global Burden of Disease Global Health Humans Incidence Male Medical research Medicine, Experimental Mortality Original Paper Parkinson Disease - epidemiology Parkinson's disease Quality-Adjusted Life Years |
title | Burden of Parkinson Disease in China, 1990–2019: Findings from the 2019 Global Burden of Disease Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T23%3A59%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Burden%20of%20Parkinson%20Disease%20in%20China,%201990%E2%80%932019:%20Findings%20from%20the%202019%20Global%20Burden%20of%20Disease%20Study&rft.jtitle=Neuroepidemiology&rft.au=Zheng,%20Zhilin&rft.date=2023-03-01&rft.volume=57&rft.issue=1&rft.spage=51&rft.epage=64&rft.pages=51-64&rft.issn=0251-5350&rft.eissn=1423-0208&rft_id=info:doi/10.1159/000527372&rft_dat=%3Cgale_karge%3EA742661836%3C/gale_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2729522137&rft_id=info:pmid/36288688&rft_galeid=A742661836&rfr_iscdi=true |